Weight-loss drugs boom could lead to beer sales drop, Heineken warns British pubs
Heineken flags possible sales impact
Heineken has cautioned British bars and pubs that rising popularity of weight-loss drugs may lead to weaker beer and cider sales. A document reported by Reuters raised the possibility that multi-pint drinking sessions could happen less often. The company said it had observed some changes in how GLP-1 users consume and would keep tracking how those habits develop in 2027.
GLP-1 use and drinking habits
Use of GLP-1 medicines has grown as consumers look for ways to lose weight quickly. JP Morgan research cited in the report said 10 million people in the US used medication for weight loss last year.
Surveys from research firms including Circana, NIQ and KAM have also indicated reduced drinking among people using GLP-1 drugs. The article says medicines such as Wegovy can lessen the desire to drink alcohol.
Heineken’s drinks portfolio
Heineken is the world’s second-largest brewer, according to the article. Its brands include Heineken lager, Amstel, Mexican lager Sol and Strongbow cider. The potential shift in consumer behaviour could therefore affect more than one category in the company’s portfolio, as the warning covers both beer and cider sales.
Key points
- Heineken says rising use of weight-loss drugs could weaken beer and cider sales in British pubs and bars.
- A Reuters-revealed document warned multi-pint sessions could become less frequent.
- JP Morgan research put US medication use at 10 million people last year.
- Circana, NIQ and KAM surveys point to reduced drinking among GLP-1 users.